Thousands stranded, 5 killed, as heavy rain lashes south China

1 / 4
This aerial photo taken on June 9, 2019 shows a general view of submerged buildings after heavy rain caused flooding in Rongan in China's southern Guangxi region. (AFP)
2 / 4
This photo taken on June 9, 2019 shows cars driving through floodwater in Rongan in China's southern Guangxi region after heavy rainstorm hit the area. (AFP)
3 / 4
This aerial photo taken on June 9, 2019 shows streets submerged by floodwater in Guilin in China's southern Guangxi region after heavy rainstorm hit the area. (AFP)
4 / 4
Paramilitary officers rescue stranded villagers at a flooded field in Quanzhou county, Guilin, Guangxi Zhuang Autonomous Region, China June 9, 2019. (Reuters)
Updated 11 June 2019

Thousands stranded, 5 killed, as heavy rain lashes south China

  • Rainfall in Jiangxi reached as much as 688 millimeters (27 inches), according to a notice by China’s meteorological administration

SHANGHAI: Thousands of people have been stranded and at least five killed amid torrential rain throughout central and southern China, with authorities bracing themselves for at least another four days of downpours, state media reported on Tuesday.
The official China Daily said floods had wiped out 10,800 hectares of crops and destroyed hundreds of houses in the Jiangxi province by Monday, with a total of 1.4 million people affected and direct economic losses amounting to 2.65 billion yuan ($382.41 million).
In the region of Guangxi in the southwest, 20,000 households had their power cut and roads, bridges and other infrastructure were severely damaged, the China Daily said.
Rainfall in Jiangxi reached as much as 688 millimeters (27 inches), according to a notice by China’s meteorological administration. It said rain in parts of Jiangxi and Hunan had hit record highs for June.
The administration said rainstorms were expected to spread to Guangdong, Fujian, Jiangxi, Yunnan, Sichuan and Taiwan by Thursday. It also warned authorities to be on their guard against severe thunderstorms and the possibility of small rivers bursting their banks in coming days. ($1 = 6.9298 Chinese yuan renminbi)


Indonesia begins human trials of anti-virus vaccine

Updated 30 min 31 sec ago

Indonesia begins human trials of anti-virus vaccine

  • The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday
  • The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines

JAKARTA: Indonesia is stepping up efforts to find a COVID-19 vaccine by launching human trials of a potentially effective drug amid criticism of its lacklustre handling of the pandemic and concerns about its plummeting economy.

The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday and is being conducted by the Padjadjaran University School of Medicine at six locations in Bandung, West Java province, where the university and the state-owned pharma company are based.

“The first day of the trial went well, with 20 volunteers in each of the six locations injected with the potential vaccine. We have no complaints so far, and we are preparing the second injection batch on Aug 14,” Iwan Setiawan, a spokesman for Bio Farma, told Arab News on Wednesday.

He added that the six-month trial would require the participation of 1,620 volunteers who were “in good health and had not tested positive” for the disease.

Ridwan Kamil, governor of West Java, Indonesia’s most populated province, is among the volunteers who have signed up for the trial.

The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines.

“The potential vaccine had gone through three trials; the pre-clinical, the clinical trial first phase and the second phase in China,” Bio Farma CEO Honesti Basyir said in a statement.

According to Basyir, Sinovac is one of the few institutions that have progressed to the third phase of the clinical trial from among hundreds of research institutions around the world that are developing the COVID-19 vaccine.

According to Oxford Business Group’s COVID-10 Economic Impact Assessment, there are more than 150 different vaccines that international researchers are working on. However, only 26 have reached the human trial stage so far.

Once the trials are concluded, Bio Farma will register the vaccine with the Food and Drug Supervisory Agency so that it can begin mass-production of the drug.

“We have prepared a production facility for the COVID-19 vaccine with a maximum capacity of 100 million dosages, and by the end of December this year we will have an increased production capacity to produce an additional 150 million dosages,” Basyir said.

President Joko Widodo oversaw the first injections to the batch of volunteers in one of the six locations and also toured Bio Farma’s production facility. 

“We hope this clinical trial would conclude in six months and so we can start producing the vaccine in January and vaccinate our people soon,” Widodo said.

State-Owned Enterprise Minister Erick Thohir, who is also the head of the COVID-19 mitigation and national economic recovery committee, said that Bio Farma was a well-established vaccine producer whose products were halal-compliant and used in 150 countries, including in the Middle East.

The collaboration with Sinovac is one of three vaccine-development projects that Indonesia is engaging in with foreign parties as it grapples with a surge in infections. At the same time, social restrictions and economic activities were eased. The other two projects are with South Korea’s Genexine and Norway’s Coalition for Epidemic, Preparedness and Innovation.

As of Wednesday, Indonesia had reported 130,718 infections with 1,942 new cases, 85,798 recoveries and 5,903 deaths, although experts suggest that the numbers could be higher due to the country’s low testing capacity.

Cases also surged in the capital Jakarta with workplaces emerging as the new infection clusters after thousands of employees returned to work recently.